This promotional webinar has been funded by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance and organised in partnership with Guidelines. See the bottom of the page for the full disclaimer.

Prescribing and adverse event reporting information.

Free webinar: Tuesday 3 November 2020,12.30–13.30

VTE webinar banner

The purpose of this Guidelines webinar is to:

  • describe the clinical presentation and recognition of venous thromboembolism (VTE) in primary care
  • discuss the pharmacological treatment options for VTE, and the clinical data supporting their use
  • clarify which patients should receive long-term treatment and what this consists of, with reference to relevant published guidance.

Watch presentations from expert speakers:

Dr-Yassir-Javaid_v2

Edward Middletn

Dr Yassir Javaid
Cardiovascular and Diabetes Lead Nene CCG;
Primary Care Cardiovascular Lead, East Midlands Clinical Network;
RCGP Clinical Adviser for Cardiology

 

Dr Edward Middleton
Consultant in Acute Medicine
Hull Royal Infirmary

 

 

Click here to register for free

This promotional webinar is intended for healthcare professionals working in the NHS. Use the link above to register. To contact Bristol Myers Squibb for any other purpose, please call 0800 731 1736. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App. Adverse events should also be reported to Bristol Myers Squibb via medical.information@bms.com or 0800 731 1736.

This promotional webinar has been funded by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance, and organised in conjunction with Guidelines. Bristol Myers Squibb has reviewed the scope of the webinar, chosen and commissioned the speakers, and approved all materials related to the webinar. Bristol Myers Squibb has paid the speakers honoraria. The views and opinions of the speakers are not necessarily those of the BMS – Pfizer Alliance, Guidelines, its publisher, advisers, or advertisers.

432UK2000675-09
Date of preparation: September 2020